Empirical antimicrobial monotherapy in patients after high‐dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial
Open Access
- 29 June 2005
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 130 (2) , 265-270
Abstract
Summary: We report on 232 patients undergoing autologous haematopoietic stem cell transplantation (ASCT) entered into a multicentre, randomised trial comparing the efficacy and tolerability of meropenem (MPM) with that of piperacillin/tazobactam (P/T) as empirical antimicrobial first‐line therapy for febrile neutropenia. In 27·6% of patients in the MPM group and 22·4% in the P/T group, therapy was initially supplemented with a glycopeptide for venous catheter infection or bacteraemia because of coagulase‐negative staphylococci. Complete response rate after 72 h was 63·8% in the MPM group and 49·6% in the P/T group (P = 0·034). Overall complete response rate after treatment modification was 94·0% in the MPM group and 93·1% in the P/T group. Median time to defervescence was 2 d in the MPM group and 3 d in the P/T group. The most frequently isolated pathogens were Gram‐positive cocci. Treatment was well tolerated in both groups. One patient (0·4%) died from infection. Empirical first‐line therapy with MPM as well as with P/T is safe and effective in febrile episodes emerging after ASCT. Higher response rates to primary treatment can be achieved with MPM.Keywords
This publication has 21 references indexed in Scilit:
- A Multicenter, Double‐Blind, Placebo‐Controlled Trial Comparing Piperacillin‐Tazobactam with and without Amikacin as Empiric Therapy for Febrile NeutropeniaClinical Infectious Diseases, 2001
- Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumorsBone Marrow Transplantation, 2001
- Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer ChemotherapyNew England Journal of Medicine, 1999
- Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable optionBone Marrow Transplantation, 1999
- Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantationBone Marrow Transplantation, 1998
- Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplantsBone Marrow Transplantation, 1998
- Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centersBone Marrow Transplantation, 1997
- Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantationBone Marrow Transplantation, 1997
- Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patientsJournal of Antimicrobial Chemotherapy, 1995
- Early infectious complications after peripheral blood stem cell autografts in childrenMedical and Pediatric Oncology, 1991